BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28988162)

  • 1. Organised screening for cervical cancer in France: a cost-effectiveness assessment.
    Barré S; Massetti M; Leleu H; De Bels F
    BMJ Open; 2017 Oct; 7(10):e014626. PubMed ID: 28988162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and costs of using HPV testing to screen for cervical cancer.
    Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
    JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
    Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
    BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria.
    Sroczynski G; Esteban E; Widschwendter A; Oberaigner W; Borena W; von Laer D; Hackl M; Endel G; Siebert U
    Int J Cancer; 2020 Aug; 147(4):1131-1142. PubMed ID: 31872420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
    Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
    J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
    Felix JC; Lacey MJ; Miller JD; Lenhart GM; Spitzer M; Kulkarni R
    J Womens Health (Larchmt); 2016 Jun; 25(6):606-16. PubMed ID: 27023044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.
    Vassilakos P; Poncet A; Catarino R; Viviano M; Petignat P; Combescure C
    Gynecol Oncol; 2019 Apr; 153(1):92-99. PubMed ID: 30718124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
    Kim JJ; Wright TC; Goldie SJ
    JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile.
    Ferreccio C; Barriga MI; Lagos M; Ibáñez C; Poggi H; González F; Terrazas S; Katki HA; Núñez F; Cartagena J; Van De Wyngard V; Viñales D; Brañes J
    Int J Cancer; 2013 Feb; 132(4):916-23. PubMed ID: 22684726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis.
    Kulasingam SL; Rajan R; St Pierre Y; Atwood CV; Myers ER; Franco EL
    BMC Med; 2009 Nov; 7():69. PubMed ID: 19900264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.
    Gage JC; Schiffman M; Katki HA; Castle PE; Fetterman B; Wentzensen N; Poitras NE; Lorey T; Cheung LC; Kinney WK
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25038467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening capacity and cost-effectiveness of the human papillomavirus test versus cervicography as an adjunctive test to Pap cytology to detect high-grade cervical dysplasia.
    Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
    Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():112-116. PubMed ID: 30682600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.
    Vijayaraghavan A; Efrusy MB; Mayrand MH; Santas CC; Goggin P
    Can J Public Health; 2010; 101(3):220-5. PubMed ID: 20737813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
    Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
    J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
    Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
    JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
    Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
    Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and Cost Effectiveness of Three Approaches for Cervical Cancer Screening among HIV-Positive Women in Johannesburg, South Africa.
    Lince-Deroche N; Phiri J; Michelow P; Smith JS; Firnhaber C
    PLoS One; 2015; 10(11):e0141969. PubMed ID: 26569487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.